Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- PE ratio
- —
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 7,000
- Avg volume
- 12,136
- Day's range
- $1.00 – $1.00
- Shares out
- —
- Stochastic %K
- 0%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- —
Company profile
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) w...
Show more
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 46 8 52 23 07 00
- Website
- https://www.mobergpharma.se
- Address
- Gustavslundsvägen 42, Bromma, Sweden
Latest news
No headlines yet.
